Olema Oncology Engages with Investors and Industry Leaders
Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA) is a pioneering clinical-stage biopharmaceutical company dedicated to revolutionizing breast cancer treatment. As part of their ongoing commitment to innovation, Olema will be prominently featured in several upcoming investor conferences, aiming to share insights into their groundbreaking work in targeted therapies.
Upcoming Investor Conferences Highlighting Olema's Advancements
Investors and stakeholders can look forward to the following notable events:
Citi’s 2025 Biopharma Back to School Conference
This conference will take place on September 2, 2025, at 4 p.m. ET, and will feature a fireside chat format, allowing for dynamic discussions around the latest advancements in biopharma.
Wells Fargo 2025 Healthcare Conference
On September 3, 2025, at 3:45 p.m. ET, Olema will present at this significant healthcare conference, presenting their innovative strategies and breakthroughs in therapy development.
Cantor Global Healthcare Conference 2025
Scheduled for September 4, 2025, at 11:30 a.m. ET in New York, Olema will once again engage with attendees through an interactive fireside chat, sharing the latest developments in their research pipeline.
Morgan Stanley Annual Global Healthcare Conference
This important conference will occur on September 8, 2025, at 10 a.m. ET, with Olema participating in a concise fireside chat to discuss their ongoing projects and future direction.
H.C. Wainwright 27th Annual Global Investment Conference
Finally, on September 9, 2025, at 9:30 a.m. ET, Olema will contribute to this prestigious conference, focusing on their innovations and commitment to improving patient outcomes in breast cancer treatment.
Brand Commitment to Breast Cancer Treatment
Olema Oncology is committed to improving standards of care for patients with breast cancer through advanced treatment methodologies. Their flagship candidate, palazestrant (OP-1250), is renowned for being a complete estrogen receptor antagonist and is currently in advanced stages of clinical trials with the OPERA-01 study. This innovative approach positions Olema at the forefront of developing therapies that are designed to address the unique challenges of endocrine-driven cancers.
Cutting-edge Research and Development
Aside from palazestrant, Olema is also advancing OP-3136, a KAT6 inhibitor currently in Phase 1 clinical trials. The development of this therapy underscores Olema's unwavering dedication to discovering new treatment paths that address resistance to existing therapies, providing hope to patients and families affected by breast cancer.
Empowering Patients with Innovative Solutions
Headquartered in San Francisco, with operations in Cambridge, Massachusetts, Olema is strategically positioned to lead in the biopharmaceutical industry. Their mission is clear: to elevate the quality of life for patients through tailored therapy solutions. For those interested in the detailed insights and outcomes from the upcoming conferences, recorded webcasts will be available via Olema’s investor relations website.
Contact Information for Media Inquiries
For additional information or inquiries, you can reach out to:
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
Frequently Asked Questions
What conferences is Olema Oncology participating in?
Olema Oncology will participate in five key investor conferences including the Wells Fargo Healthcare Conference and the Morgan Stanley Annual Global Healthcare Conference.
What is Olema's main focus area in biopharmaceuticals?
Olema focuses on discovering and developing targeted therapies specifically for breast cancer treatment.
What is palazestrant and why is it significant?
Palazestrant (OP-1250) is Olema’s leading product candidate, a complete estrogen receptor antagonist in advanced trials aiming to address breast cancer effectively.
How can investors connect with Olema during these conferences?
Investors can join live webcasts of the presentations as permitted during the events, or visit Olema’s investor relations section for recordings.
Where can I find more information about Olema Oncology?
Detailed insights about Olema Oncology and their ongoing projects can be found on their official website at www.olema.com.